Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We determined CYP2D6*4 and CYP2D6* genotypes and metabolizer phenotypes in 96 patients with suspected malaria in Venezuela and found intermediate or poor metabolizer phenotypes in ≈25% of cases. Nine of 44 malaria patients had Plasmodium vivax recurrence. Public health authorities should evaluate the benefits of increasing total doses of primaquine for treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407200 | PMC |
| http://dx.doi.org/10.3201/eid3109.250316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
pneumonia in thoracic organ transplantation: Current perspectives and updates.
JHLT Open
November 2025
Professor of Medicine, Transplant Infectious Diseases and Transplant Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
pneumonia (PCP) is an opportunistic infectious disease in thoracic solid organ transplant (SOT) recipients, occurring particularly in the setting of augmented immunosuppression. Thoracic allograft recipients are particularly at risk of severe outcomes. Diagnosis is frequently delayed due to nonspecific clinical findings and challenges in ruling out other opportunistic pathogens and distinguishing between pneumonia and colonization.
View Article and Find Full Text PDFCYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela.
Emerg Infect Dis
September 2025
We determined CYP2D6*4 and CYP2D6* genotypes and metabolizer phenotypes in 96 patients with suspected malaria in Venezuela and found intermediate or poor metabolizer phenotypes in ≈25% of cases. Nine of 44 malaria patients had Plasmodium vivax recurrence. Public health authorities should evaluate the benefits of increasing total doses of primaquine for treatment.
View Article and Find Full Text PDFEfficacy and gametocyte carriage in Plasmodium falciparum cases treated with artemether-lumefantrine alone versus with single-dose primaquine in Ethiopia: A randomized controlled study.
Acta Trop
August 2025
Department of Biology, Arba Minch University, Arba Minch, Ethiopia. Electronic address:
This study evaluated the efficacy of adding primaquine (PQ) to artemether-lumefantrine (AL) for treating uncomplicated Plasmodium falciparum malaria in Ethiopia. Asexual parasite clearance was monitored with microscopy and molecular techniques, while gametocyte clearance was observed solely through microscopy. Genotyping to distinguish recrudescence from reinfection was performed using nested polymerase chain reaction (PCR).
View Article and Find Full Text PDFImported plasmodium ovale malaria from Côte d'Ivoire: a case report.
Trop Dis Travel Med Vaccines
August 2025
Internal medicine department, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Background: Malaria remains a significant global health issue, with an estimated 263 million cases and 597,000 deaths reported in 2023. Plasmodium ovale, although less common than P. falciparum and P.
View Article and Find Full Text PDFSingle low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.
BMJ Glob Health
August 2025
UR3073, University of Strasbourg, Strasbourg, France
Since 2012, the WHO has recommended a single low dose of primaquine (SLDPQ, 0.25 mg/kg) alongside artemisinin-based combination therapies (ACTs) to block transmission and combat artemisinin resistance. Despite its proven benefits, SLDPQ adoption in African malaria policies remains limited.
View Article and Find Full Text PDF